Savara Inc. (NASDAQ:SVRA) Q2 2020 Earnings Conference Call - Final Transcript

Aug 06, 2020 • 04:30 pm ET

Previous

Savara Inc. (NASDAQ:SVRA) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Welcome to the Savara conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call will be available on the Investors section of Savara's Web site, at savarapharma.com. This call is subject to copyright and is the property of Savara. All recordings, reproduction, and transmission of this call without the expressed written consent of Savara is strictly prohibited. As a reminder, today's call is being recorded.

I would now like to turn the call over to Anne Erickson, Head Investor Relations and Corporate Communications at Savara.

Executive
Anne Erickson

Good afternoon and thank you for joining us today. A press release reporting our second quarter 2020 financial results was issued earlier today, August 6, 2020, and can be found on the Investors section of our Web site, at savarapharma.com. If you have not received this release or you would like to be added to the company's distribution list, please e-mail me at ir@savarapharma.com.

This call is also being webcast live, and one hour after the call a replay will be available on the company's Web site, and will remain available for the next 30-days. A telephone replay will be available through August 13.

Today's conference call and webcast contain forward-looking statements within the meaning of federal securities laws, including statements regarding the company's strategy, goals, product candidates, clinical studies, and financing matters. Such statements are subject to significant risks and uncertainties, including those described in our press release issued today, Thursday, August 6, 2020, and our recent SEC filings on Forms 8-K, 10-K, and 10-Q.

Actual results or performance may differ materially from the expectations indicated by our forward-looking statements due to those risks and uncertainties. We caution you not to place undue reliance on any of the forward-looking statements, which speak only as of today. We will take analysts' questions at the end of the call; however, we encourage shareholders to submit questions via e-mail to ir@savarapharma.com. Time permitting; we will address these questions alongside any others received by our IR team.

Joining me on the call today are Rob Neville, Chief Executive Officer; Badrul Chowdhury, Chief

Medical Officer; Taneli Jouhikainen, President and Chief Business Officer; and Dave Lowrance, Chief Financial Officer.

I will now turn the call over to Rob.

Executive
Robert Neville

Thank you, Anne, and good afternoon, everybody. Let me start by saying that I'm pleased with the progress we are making across our top line. Most notably, the value program - estimate that we now have finalized design for the Phase III IMPALA 2 clinical study.

In a few minutes, Badrul will walk you through all the details. First let me share at the technical team has been working diligently to get the operational aspects of the study in place and finalize, so that we can get the study up and running as soon as possible.

One component of that work is taking prudent proactive steps to determine how to COVID proof the study as best we can. While we hope there will be no